Table 3.
Characteristics of MRONJ Patients
| Characteristics | Total (n=52) | IV Bisphosphonates (n = 20) | Denosumab (n = 23) | IV BP/Denosumab (n = 9) |
|---|---|---|---|---|
| Age (Years) (Mean ± SD) | 62.0 ± 10.4 | 58.9 ± 11.9 | 62.4 ± 8.8 | 67.8 ± 8.9 |
| Female sex, n (%) | 39 (75%) | 15 (75%) | 16 (69.6%) | 8 (88.9%) |
| Race | ||||
| White/Non-Hispanic | 41 (71.6%) | 14 (70.0%) | 20 (87.0%) | 7 (77.8%) |
| Black/Non-Hispanic | 8 (15.4%) | 5 (25.0%) | 2 (8.7%) | 1 (11.1%) |
| Hispanic | 2 (3.8%) | 0 | 1 (4.4%) | 1 (11.1%) |
| Other | 1 (1.9%) | 1 (5.0%) | 0 | 0 |
| Comorbidity | ||||
| Diabetes | 13 (25.0%) | 5 (25.0%) | 5 (21.7%) | 3 (33.3%) |
| Hyperlipidemia | 26 (50.0%) | 7 (35.0%) | 14 (60.9%) | 5 (55.6%) |
| Obesity | 14 (26.9%) | 7 (35.0%) | 4 (17.4%) | 3 (33.3%) |
| Exposure to other medications related to MRONJ | ||||
| Antiangiogenic meds | 4 (7.7%) | 1 (5.0%) | 1 (4.4%) | 2 (22.2%) |
| mTOR inhibitors | 5 (9.6%) | 1 (5.0%) | 3 (13.0%) | 1 (11.1%) |
| Dental surgery | 3 (5.8%) | 0 | 2 (8.7%) | 1 (11.1%) |